Abstract
Second generation antipsychotics (SGAs) are increasingly employed in the treatment of depression. Adjunctive aripiprizole and olanzapine/fluoxetine combination (OFC) have been approved in the US in the treatment of depression. Quetiapine also appears to be poised for an FDA approval as an adjunctive treatment for resistant depression. Historically, first generation antipsychotics were thought to carry an enhanced risk of certain side effects in the treatment of mood disorders, including an enhanced risk of extrapyramidal symptoms (EPS). The second generation antipsychotics are also known to be associated with a variety of metabolic side effects. The use of SGA in a depressed population may pose risks that differ from use in other conditions such as bipolar disorder and schizophrenia. In this paper, the risk of extrapyramidal and metabolic side effects is reviewed in depressed patients treated with second generation antipsychotics.
Keywords: Major depression, drug treatment, anti-psychotics, toxicity
Current Drug Safety
Title: Safety Considerations of the Use of Second Generation Antipsychotics in the Treatment of Major Depression: Extrapyramidal and Metabolic Side Effects
Volume: 5 Issue: 3
Author(s): Charles DeBattista and Kristina DeBattista
Affiliation:
Keywords: Major depression, drug treatment, anti-psychotics, toxicity
Abstract: Second generation antipsychotics (SGAs) are increasingly employed in the treatment of depression. Adjunctive aripiprizole and olanzapine/fluoxetine combination (OFC) have been approved in the US in the treatment of depression. Quetiapine also appears to be poised for an FDA approval as an adjunctive treatment for resistant depression. Historically, first generation antipsychotics were thought to carry an enhanced risk of certain side effects in the treatment of mood disorders, including an enhanced risk of extrapyramidal symptoms (EPS). The second generation antipsychotics are also known to be associated with a variety of metabolic side effects. The use of SGA in a depressed population may pose risks that differ from use in other conditions such as bipolar disorder and schizophrenia. In this paper, the risk of extrapyramidal and metabolic side effects is reviewed in depressed patients treated with second generation antipsychotics.
Export Options
About this article
Cite this article as:
DeBattista Charles and DeBattista Kristina, Safety Considerations of the Use of Second Generation Antipsychotics in the Treatment of Major Depression: Extrapyramidal and Metabolic Side Effects, Current Drug Safety 2010; 5 (3) . https://dx.doi.org/10.2174/157488610791698325
DOI https://dx.doi.org/10.2174/157488610791698325 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design Adolescent Alcohol Abuse and Dependence: Development, Diagnosis, Treatment and Outcomes
Current Psychiatry Reviews Targeting Trypanosoma cruzi Platelet-activating Factor Receptors: Scope for the Development of Novel Drugs to Treat Chagas Disease
Mini-Reviews in Medicinal Chemistry Adenosine in the Inflamed Gut: A Janus Faced Compound
Current Medicinal Chemistry Cardiac Adrenomedullin: Its Role in Cardiac Hypertrophy and Heart Failure
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach
Current Pharmaceutical Design Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy A2A Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Nicotine Vaccines
CNS & Neurological Disorders - Drug Targets NMDA Receptor Antagonists as Antidepressant and Antidementia Drugs: Recent Developments and Future Prospects
Current Medicinal Chemistry - Central Nervous System Agents Rho Kinase Inhibitors and Novel Ocular Drug Delivery Systems- A Revolutionary Step Towards the Treatment of Glaucoma
Current Drug Delivery β-Adrenomimetic Actions in the Hypotension and Vasodilatation Induced by a Chromatographic Active Fraction from Bidens pilosa L. (Asteraceae) in Mammals
Current Bioactive Compounds Microbial Polysaccharides and their Derivatives as Current and Prospective Pharmaceuticals
Current Pharmaceutical Design The Complexes of Drugs with Carbohydrate-Containing Plant Metabolites as Pharmacologically Promising Agents
Mini-Reviews in Medicinal Chemistry Mitochondrial Biogenesis: Regulation By Endogenous Gases During Inflammation and Organ Stress
Current Pharmaceutical Design Physiopathological Roles of P2X Receptors in the Central Nervous System
Current Medicinal Chemistry A Review of Chemistry and Pharmacology of Piperidine Alkaloids of Pinus and Related Genera
Current Pharmaceutical Biotechnology Endoplasmic Reticulum Stress and Atherosclerosis
Current Hypertension Reviews Safe and Effective Delivery of Amphotericin B: A Survey of Patents
Recent Patents on Nanotechnology Scope and Limitations of The Co-Drug Approach to Topical Drug Delivery
Current Pharmaceutical Design